MX2021005776A - Formulaciones farmaceuticas para administracion subcutanea. - Google Patents

Formulaciones farmaceuticas para administracion subcutanea.

Info

Publication number
MX2021005776A
MX2021005776A MX2021005776A MX2021005776A MX2021005776A MX 2021005776 A MX2021005776 A MX 2021005776A MX 2021005776 A MX2021005776 A MX 2021005776A MX 2021005776 A MX2021005776 A MX 2021005776A MX 2021005776 A MX2021005776 A MX 2021005776A
Authority
MX
Mexico
Prior art keywords
subcutaneous administration
pharmaceutical formulations
monophosphate
compositions
weight
Prior art date
Application number
MX2021005776A
Other languages
English (en)
Inventor
Nancy Sever
Ehab Moussa
Matthew Rosebraugh
Feroz Jameel
Maurizio F Facheris
Weining Z Robieson
Charles S Locke
Sven Stodtmann
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2021005776A publication Critical patent/MX2021005776A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere a composiciones de levodopa 4'-monofosfato y carbidopa 4'-monofosfato que tienen una relación peso a peso de aproximadamente 20:1 y métodos para tratar la enfermedad de Parkinson y afecciones asociadas mediante la administración subcutánea de tales composiciones.
MX2021005776A 2018-11-15 2019-11-15 Formulaciones farmaceuticas para administracion subcutanea. MX2021005776A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862767546P 2018-11-15 2018-11-15
US201962843945P 2019-05-06 2019-05-06
US201962863113P 2019-06-18 2019-06-18
US201962863101P 2019-06-18 2019-06-18
US201962863093P 2019-06-18 2019-06-18
US201962898214P 2019-09-10 2019-09-10
PCT/US2019/061626 WO2020102628A1 (en) 2018-11-15 2019-11-15 Pharmaceutical formulations for subcutaneous administration

Publications (1)

Publication Number Publication Date
MX2021005776A true MX2021005776A (es) 2021-07-02

Family

ID=68835352

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005776A MX2021005776A (es) 2018-11-15 2019-11-15 Formulaciones farmaceuticas para administracion subcutanea.

Country Status (14)

Country Link
US (1) US20200155578A1 (es)
EP (1) EP3880210A1 (es)
JP (1) JP2022507528A (es)
KR (1) KR20210091139A (es)
CN (1) CN113015531A (es)
AU (1) AU2019379806A1 (es)
BR (1) BR112021009353A2 (es)
CA (1) CA3117983A1 (es)
IL (1) IL282842A (es)
MX (1) MX2021005776A (es)
SG (1) SG11202104499RA (es)
TW (1) TW202031265A (es)
UY (1) UY38473A (es)
WO (1) WO2020102628A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023049534A2 (en) 2021-10-27 2023-03-30 Abbvie Inc. Subcutaneously administered treatments for advanced parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65060B1 (sr) 2014-03-13 2024-02-29 Neuroderm Ltd Sastavi inhibitora dopa dekarboksilaze
AU2015335941B2 (en) * 2014-10-21 2021-04-01 Abbvie Inc. Carbidopa and L-dopa prodrugs and their use to treat Parkinson's disease
BR112019001229B1 (pt) 2016-07-22 2022-11-16 Syngenta Participations Ag Composto derivado de oxadiazol, composição agroquímica compreendendo o mesmo, método para controlar ou impedir infestação de plantas úteis por microrganismos fitopatogênicos e uso do referido composto como fungicida
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
UY38473A (es) 2020-06-30
BR112021009353A2 (pt) 2021-11-23
SG11202104499RA (en) 2021-05-28
EP3880210A1 (en) 2021-09-22
IL282842A (en) 2021-06-30
CN113015531A (zh) 2021-06-22
TW202031265A (zh) 2020-09-01
CA3117983A1 (en) 2020-05-22
KR20210091139A (ko) 2021-07-21
AU2019379806A1 (en) 2021-05-27
JP2022507528A (ja) 2022-01-18
US20200155578A1 (en) 2020-05-21
WO2020102628A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
MX2019012676A (es) Derivados de 2-aminoquinolina.
ZA202110659B (en) Methods of reducing the risk of cardiovascular events in a subject
SA521421115B1 (ar) عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام
AU2018243463A8 (en) 11,13-modified saxitoxins for the treatment of pain
EP4295909A3 (en) Carbidopa and l-dopa prodrugs and methods of use
WO2018111315A8 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
JOP20200134A1 (ar) تركيبات وطرق لمعالجة حالات أيضية
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
PH12021550043A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
SG10201907291QA (en) Monomethylfumarate prodrug compositions
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
BR112022003659A2 (pt) Composições e métodos de tratamento de doenças vasculares
MX2019003470A (es) Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2021005776A (es) Formulaciones farmaceuticas para administracion subcutanea.
MX2021012543A (es) Compuestos de indoles quirales y su uso.
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2021015732A (es) Administracion intranasal de merotocina para mejorar la lactancia.
AU2019296851A8 (en) Application of composition of D-mannuronic diacid in treatment of Parkinson's disease
AR117097A1 (es) Formulaciones farmacéuticas para una administración subcutánea
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6
MX2021013489A (es) Combinacion farmaceutica que comprende trazodona para el tratamiento del dolor neuropatico.
PH12021500016A1 (en) Methods of reducing the risk of cardiovascular events in a subject